A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503615-14-00

Acronym

MK-4280A-008

Enrollment

Registered

2023-08-02

Start date

2022-09-29

Completion date

2025-12-31

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Classical Hodgkin Lymphoma

Brief summary

Progression-Free Survival (PFS) per Lugano Response Criteria as Assessed by Investigator

Detailed description

Overall Survival (OS), Objective Response Rate (ORR) per Lugano Response Criteria as Assessed by Investigator, Duration of Response (DOR) per Lugano Response Criteria as Assessed by Investigator, Number of Participants Who Experienced At Least One Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

Interventions

DRUGGEMCITABINE

DRUGMK-4280A

DRUGBENDAMUSTINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS) per Lugano Response Criteria as Assessed by Investigator	—

Secondary

Measure	Time frame
Overall Survival (OS), Objective Response Rate (ORR) per Lugano Response Criteria as Assessed by Investigator, Duration of Response (DOR) per Lugano Response Criteria as Assessed by Investigator, Number of Participants Who Experienced At Least One Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)	—

Countries

Belgium, Czechia, France, Germany, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026